The stock of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) is a huge mover today! The stock decreased 18.00% or $0.9 on November 11, hitting $4.1. About 87,799 shares traded hands or 33.73% up from the average. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has risen 157.73% since April 11, 2016 and is uptrending. It has outperformed by 151.59% the S&P500.
The move comes after 8 months negative chart setup for the $64.98M company. It was reported on Nov, 11 by Barchart.com. We have $3.61 PT which if reached, will make NYSEMKT:NBY worth $7.80 million less.
Analysts await NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) to report earnings on November, 15.
According to Zacks Investment Research, “NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus.”
More notable recent NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) news were published by: Marketwatch.com which released: “NovaBay Pharmaceuticals Inc.” on July 16, 2010, also Businesswire.com with their article: “NovaBay Pharmaceuticals to Hold Third Quarter 2016 Conference Call on November 10” published on November 03, 2016, Quotes.Wsj.com published: “News NovaBay Pharmaceuticals Inc.NBY” on February 11, 2011. More interesting news about NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) were released by: Businesswire.com and their article: “NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova …” published on November 19, 2015 as well as Businesswire.com‘s news article titled: “NovaBay Pharmaceuticals Announces Partnership with ALPHAEON to Bring Avenova …” with publication date: September 24, 2015.
NBY Company Profile
NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., incorporated on April 19, 2010, is a biopharmaceutical company, which develops products for the eye care market. The Firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. The Company’s Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.